{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:28:55Z","timestamp":1793053735742,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006280","name":"Urology Care Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euo.2024.01.015","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T20:33:11Z","timestamp":1709757191000},"page":"1358-1366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Magnetic Resonance Imaging\u2013based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study"],"prefix":"10.1016","volume":"7","author":[{"given":"Andrew E.","family":"Amini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Almashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen J.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R","family":"O'Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley R.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-4558","authenticated-orcid":false,"given":"Keyan","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.01.015_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2024.01.015_b0010","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","article-title":"The heritability of prostate cancer in the Nordic Twin Study of Cancer","volume":"23","author":"Hjelmborg","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2024.01.015_b0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.01.015_b0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0025","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2024.01.015_b0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0035","first-page":"15708","article-title":"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.euo.2024.01.015_b0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2021.10.036","article-title":"Inherited TP53 variants and risk of prostate cancer","volume":"81","author":"Maxwell","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.015_b0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.015_b0050","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN Guidelines\u00ae insights: prostate cancer early detection, version 1.2023","volume":"21","author":"Moses","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2024.01.015_b0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.01.015_b0065","article-title":"EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer","author":"Mottet","year":"2023","journal-title":"Milan"},{"key":"10.1016\/j.euo.2024.01.015_b0070","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers\u2014results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2017.01.042","article-title":"Diagnostic performance of Prostate Imaging Reporting and Data System version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis","volume":"72","author":"Woo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.015_b0080","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0085","unstructured":"Brunson J, Read Q. ggalluvial: alluvial plots in \u201cggplot2.\u201d 2023."},{"key":"10.1016\/j.euo.2024.01.015_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euo.2024.01.015_b0095","doi-asserted-by":"crossref","unstructured":"Daniel D. Sjoberg: dcurves: decision curve analysis for model evaluation. 2022.","DOI":"10.32614\/CRAN.package.dcurves"},{"key":"10.1016\/j.euo.2024.01.015_b0100","unstructured":"R Core Team. R: a language and environment for statistical computing. 2022."},{"key":"10.1016\/j.euo.2024.01.015_b0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41416-021-01410-0","article-title":"PALB2 mutations and prostate cancer risk and survival","volume":"125","author":"Woko\u0142orczyk","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2024.01.015_b0110","doi-asserted-by":"crossref","first-page":"e000057","DOI":"10.1136\/bmjonc-2023-000057","article-title":"Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study","volume":"2","author":"Moore","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0115","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.01.015_b0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2024.01.015_b0125","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.01.015_b0130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/01.ju.0000086940.10392.93","article-title":"Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng\/ml","volume":"170","author":"Khan","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.01.015_b0135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2023.41.6_suppl.390","article-title":"Inherited risk for prostate cancer (PCa): following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI)","volume":"41","author":"Couvillon","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T19:10:58Z","timestamp":1737832258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2588931124000415"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.01.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic Resonance Imaging\u2013based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}